Egetis Therapeutics AB, formerly known as PledPharma AB, is an innovative pharmaceutical company based in Sweden that specializes in the late-stage development and commercialization of treatments for severe rare diseases with significant unmet medical needs. The company's business model is centered on the orphan drug segment, aiming to bring specialized therapies to market and potentially monetizing Priority Review Vouchers (PRVs) in the United States.
Egetis's primary asset is Emcitate (tiratricol), a small molecule thyroid hormone analogue developed for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating congenital disorder. Emcitate has received Orphan Drug Designation in both the US and the EU, and the company is actively pursuing regulatory approvals, including a New Drug Application (NDA) in the US and a Marketing Authorisation Application (MAA) in Europe. Additionally, Egetis is developing Aladote (calmangafodipir), a first-in-class drug candidate designed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose, though its development has been temporarily paused to prioritize Emcitate.
As a clinical-stage company, Egetis does not currently generate commercial product revenue and relies on equity financing to fund its operations. Geographically, the company is headquartered in Stockholm and is establishing a commercial infrastructure in Europe and the United States to support the anticipated launch of Emcitate. Its competitive position is strengthened by its focus on ultra-orphan indications where no approved therapies currently exist.
